Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC59H71N11O8 |
InChIKeyHYZMVIWTOQSXRR-YLKGYVPLSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | US | 17 May 2023 | |
Autoimmune Diseases | Preclinical | ES | 17 May 2023 | |
B-Cell Lymphoma | Preclinical | ES | 17 May 2023 | |
B-Cell Lymphoma | Preclinical | US | 17 May 2023 |